Simsek, E. T. Et Al. 2016. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9 , 810-816.

Simsek, E. T., Eskazan, A. E., Cengiz, M., AR, M. C., Ekizoglu, S., Salihoglu, A., ... Gulturk, E.(2016). Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9, 810-816.

Simsek, Eda Et Al. "Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia," JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9, 810-816, 2016

Simsek, Eda T. Et Al. "Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia." JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9, pp.810-816, 2016

Simsek, E. T. Et Al. (2016) . "Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia." JOURNAL OF CLINICAL PATHOLOGY , vol.69, no.9, pp.810-816.

@article{article, author={Eda Tanrikulu Simsek Et Al. }, title={Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia}, journal={JOURNAL OF CLINICAL PATHOLOGY}, year=2016, pages={810-816} }